We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-9.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$155M
AUM Growth
-$12.2M
(-7.3%)
Cap. Flow
+$10.8M
Cap. Flow
% of AUM
6.97%
Top 10 Holdings %
Top 10 Hldgs %
72.2%
Holding
43
New
7
Increased
12
Reduced
13
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MeiraGTx Holdings
MGTX
|
+$5.86M |
| 2 |
Charles River Laboratories
CRL
|
+$4.94M |
| 3 |
Cue Biopharma
CUE
|
+$4.82M |
| 4 |
Prothena Corp
PRTA
|
+$4.53M |
| 5 |
Shattuck Labs
STTK
|
+$3.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$5.9M |
| 2 |
Encompass Health
EHC
|
+$5.4M |
| 3 |
Oscar Health
OSCR
|
+$5.12M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.18M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.33% |
| 2 | Miscellaneous | 8.26% |
| 3 | Industrials | 1.41% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $23.2M | 14.98% |
374,000
+28,100
| +8% | +$1.72M |
|
|
2
Prothena Corp
PRTA
$479M
| $20.7M | 13.38% |
566,538
+125,538
| +28% | +$4.53M |
|
|
ALBO
3
DELISTED
Albireo Pharma Inc
ALBO
| $14.3M | 9.25% |
480,000
-34,082
| -7% | -$998K |
|
|
LKFT
4
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $12.1M | 7.81% |
195,000
-5,300
| -3% | -$324K |
|
|
5
Charles River Laboratories
CRL
$13.9B
| $8.95M | 5.78% |
31,500
+16,019
| +103% | +$4.94M |
|
|
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
| $8.69M | 5.61% |
589,270
+179,650
| +44% | +$2.58M |
|
|
7
Cue Biopharma
CUE
$203M
| $7.37M | 4.76% |
50,343
+22,708
| +82% | +$4.82M |
|
8
Aldeyra Therapeutics
ALDX
$89.9M
| $6.22M | 4.02% |
1,400,239
+244,939
| +21% | +$976K |
|
|
9
MeiraGTx Holdings
MGTX
$1.33B
| $5.27M | 3.4% |
+380,700
| New | +$5.86M |
|
|
KZR
10
DELISTED
Kezar Life Sciences
KZR
| $4.99M | 3.22% |
30,000
-6,000
| -17% | -$861K |
|
|
CNVY
11
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $4.89M | 3.16% |
748,134
-28,866
| -4% | -$191K |
|
12
Alnylam Pharmaceuticals
ALNY
$31.7B
| $3.71M | 2.39% |
22,704
-9,203
| -29% | -$1.4M |
|
13
Agilon Health
AGL
$1.55B
| $3.55M | 2.29% |
5,600
-400
| -7% | -$206K |
|
|
14
Shattuck Labs
STTK
$707M
| $3.4M | 2.2% |
798,718
+538,475
| +207% | +$3.05M |
|
15
Rocket Pharmaceuticals
RCKT
$424M
| $3.22M | 2.08% |
203,268
+74,563
| +58% | +$1.29M |
|
16
QuidelOrtho
QDEL
$1.01B
| $2.89M | 1.86% |
+25,675
| New | +$2.74M |
|
|
17
Encompass Health
EHC
$11.9B
| $2.84M | 1.83% |
50,154
-103,435
| -67% | -$5.4M |
|
|
18
Oscar Health
OSCR
$9.4B
| $2.37M | 1.53% |
237,500
-687,500
| -74% | -$5.12M |
|
|
ACCD
19
DELISTED
Accolade Inc
ACCD
| $2.18M | 1.41% |
124,393
+74,393
| +149% | +$1.37M |
|
|
SEM
20
DELISTED
Select Medical
SEM
| $2.18M | 1.41% |
+168,503
| New | +$2.22M |
|
21
CRISPR Therapeutics
CRSP
$5.58B
| $2.13M | 1.38% |
34,000
+16,636
| +96% | +$1.04M |
|
22
InMode
INMD
$855M
| $1.85M | 1.19% |
+50,000
| New | +$2.24M |
|
23
Mirum Pharmaceuticals
MIRM
$5.94B
| $1.63M | 1.05% |
+73,930
| New | +$1.51M |
|
24
Globus Medical
GMED
$11.1B
| $1.33M | 0.86% |
18,000
-2,188
| -11% | -$152K |
|
25
ARS Pharmaceuticals
SPRY
$586M
| $1.14M | 0.74% |
325,365
+271,550
| +505% | +$1.18M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2022 Portfolio in Review
As of Q1 2022, Prosight Management held 43 positions worth $155M, down 7.3% from $167M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Prosight Management deployed $10.8M of net new capital in Q1 2022, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was MeiraGTx Holdings: 380,700 shares worth $5.27M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Encompass Health, an estimated $5.4M trimmed.
- Prosight Management's largest Q1 2022 buy was MeiraGTx Holdings: 380,700 shares worth $5.27M.
- Prosight Management added most to Charles River Laboratories in Q1 2022, an estimated $4.94M increase.
- Prosight Management's biggest Q1 2022 reduction was Encompass Health, cutting an estimated $5.4M.
- Prosight Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $5.9M.
- Prosight Management's ten largest holdings make up 72% of its $155M portfolio in Q1 2022.
- Prosight Management opened 7 new positions and closed 11 in Q1 2022.
- Prosight Management's portfolio value fell 7.3% quarter-over-quarter to $155M.
Based on Prosight Management's 13F filing for Q1 2022, filed 16 May 2022.